Form 8-K BIOMARIN PHARMACEUTICAL For: Oct 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $105 at Leerink Partners
October 30, 2024 6:26 AM EDTLeerink Partners analyst Joseph Schwartz lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $105.00 (from $132.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: This time last year on the 3Q23 earnings conference call, former CEO Jean Jacques (JJ) Bienaimé publicized his retirement (effective December 1, 2023) and Alexander Hardy who was the CEO of Genentech at Roche (RHHBY, Not Rated) at... More
